Pirfenidone
- Generic Name
- Pirfenidone
- Brand Names
- Esbriet, Pirfenidone axunio (previously Pirfenidone AET), Pirfenidone Viatris
- Drug Type
- Small Molecule
- Chemical Formula
- C12H11NO
- CAS Number
- 53179-13-8
- Unique Ingredient Identifier
- D7NLD2JX7U
- Background
Pirfenidone is a synthetic pyridone drug. It is an antifibrotic agent with anti-inflammatory and antioxidant properties that is used to treat idiopathic pulmonary fibrosis (IPF), which is a chronic, progressive form of interstitial pneumonia. While its mechanism of action is not yet fully understood, pirfenidone is proposed to primarily regulate tumor necrosis factor (TNF) pathways and modulate cellular oxidation. The FDA first approved pirfenidone alongside nintedanib as one of the first drugs to treat IPF.
- Indication
Pirfenidone is indicated for the treatment of idiopathic pulmonary fibrosis (IPF). In Canada and Europe, it is approved in adults only.
- Associated Conditions
- Idiopathic Pulmonary Fibrosis (IPF), Mild Idiopathic Pulmonary Fibrosis, Moderate Idiopathic Pulmonary Fibrosis
A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- First Posted Date
- 2024-02-05
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 20
- Registration Number
- NCT06241560
- Locations
- 🇬🇪
LTD The First Medical Center, Tbilisi, Georgia
🇬🇪LTD "Aversi clinic", Tbilisi, Georgia
Perfenidone in Type 2 Diabetic Patients With Diabetic Neuropathy
- Conditions
- Diabetic NephropathiesType 2 Diabetes
- Interventions
- Other: Placebo
- First Posted Date
- 2024-01-25
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Sidrah Lodhi
- Target Recruit Count
- 60
- Registration Number
- NCT06224790
- Locations
- 🇵🇰
King Edward Medical University, Lahore, Punjab, Pakistan
Pirfenidone as a Radiosensitizer in the Treatment of Head and Neck Squamous Cell Carcinoma
- Conditions
- RadiosensitizerHead and Neck Squamous Cell CarcinomaRadiotherapyPirfenidone
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-11-21
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 66
- Registration Number
- NCT06142318
- Locations
- 🇨🇳
Fujian Provinical Hospital, Fuzhou, China
🇨🇳Jieyang people's hospital, Jieyang, China
🇨🇳Huizhou Central People's Hospital, Huizhou, China
A Study in Healthy Men to Test Whether BI 1015550 Influences the Amount of Nintedanib and Pirfenidone in the Blood
- First Posted Date
- 2023-10-06
- Last Posted Date
- 2023-12-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 14
- Registration Number
- NCT06070610
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
Biomarkers in HF: Circulating Biomarkers of Fibrosis and Cardiovascular Disease
- First Posted Date
- 2023-04-24
- Last Posted Date
- 2023-04-24
- Lead Sponsor
- Manchester University NHS Foundation Trust
- Target Recruit Count
- 107
- Registration Number
- NCT05826821
- Locations
- 🇬🇧
Manchester University NHS Foundation Trust, Manchester, United Kingdom
Pifenidone Prophylactic Therapy for Radiation Lung Injury in Patients Who Have Previously Received Immune Checkpoint Inhibitors
- First Posted Date
- 2023-04-06
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Hubei Cancer Hospital
- Target Recruit Count
- 41
- Registration Number
- NCT05801133
- Locations
- 🇨🇳
Hubei Cancer Hospital, Wuhan, Hubei, China
Dose Reduction and Discontinuation With Anti-Fibrotic Medications
- First Posted Date
- 2023-03-22
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2778
- Registration Number
- NCT05779007
- Locations
- 🇺🇸
Boehringer Ingelheim, Ridgefield, Connecticut, United States
Pirfenidone in Adult Hospitalized Patients With COVID-19
- Conditions
- COVID-19 Pneumonia
- Interventions
- First Posted Date
- 2023-02-06
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Capital Medical University
- Target Recruit Count
- 168
- Registration Number
- NCT05713292
- Locations
- 🇨🇳
China-Japan Friendship Hospital, Beijing, Beijing, China
Safety of Nintedanib in Real World in China
- First Posted Date
- 2023-01-09
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT05676112
Anti-Inflammatory and Anti-Fibrotic Drugs in Post COVID-19 Pulmonary Fibrosis
- Conditions
- Post-COVID-19 SyndromeLung Fibrosis
- Interventions
- First Posted Date
- 2022-12-13
- Last Posted Date
- 2022-12-13
- Lead Sponsor
- Mansoura University
- Target Recruit Count
- 200
- Registration Number
- NCT05648734
- Locations
- 🇪🇬
Mansoura University, Mansoura, Dakahlia, Egypt
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.